Metropolis Healthcare Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Metropolis Healthcare reported Q1 FY27 revenue growth of approximately 17% year-on-year to Rs 450 crores, driven primarily by volume growth, with EBITDA margin expanding 210 basis points to 25.2%. Patient volumes grew 10% and test volumes grew 11%, with no price increases taken over the last 18 months. Management discussed integration progress on Core Diagnostics, network expansion in Tier-2 and Tier-3 towns, and performance across B2C, B2B, Specialty and TruHealth segments.
Metropolis Healthcare reported Q4 FY26 group revenue of Rs 425 crore, up 23% year-on-year, with an EBITDA margin of 25.4%, while full year FY26 revenue reached Rs 1,646 crore, up 23.6%. Organic revenue growth for the year was 13.7%, ahead of the company's stated 12-13% guidance, with organic EBITDA margin expanding to 25.9%. Management also discussed the integration of Core Diagnostics, which reached a high-single-digit EBITDA margin in Q4, and outlined plans for network expansion including mini hubs and additional collection centers over the next three years.